Maija Lahtela-Kakkonen
Overview
Explore the profile of Maija Lahtela-Kakkonen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montanucci L, Iori S, Lahtela-Kakkonen M, Pauletto M, Giantin M, Dacasto M
Int J Mol Sci
. 2024 Dec;
25(23).
PMID: 39684241
Cytochrome P450 3A (CYP3A) enzymes catalyze the metabolism of a wide range of endogenous and exogenous compounds. Genetic variations in the 3 CYP3A isoforms (CYP3A28, CYP3A74, and CYP3A76) may influence...
2.
Rahnasto-Rilla M, Puumalainen T, Karttunen V, Adla S, Lahtela-Kakkonen M
Bioorg Med Chem
. 2024 Sep;
112:117884.
PMID: 39226716
Small molecule inhibitors targeting the bromodomain and extra-terminal domain (BET) family proteins have emerged as a promising class of anti-cancer drugs. Nevertheless, the clinical advancement of these agents has been...
3.
Sallomy C, Awolade P, Rahnasto-Rilla M, Hamalainen M, Nousiainen L, Johansson N, et al.
ACS Med Chem Lett
. 2024 Aug;
15(8):1221-1226.
PMID: 39140042
Transient receptor potential ankyrin 1 (TRPA1) protein plays an important role in the inflammatory response, and it has been associated with different pain conditions and pain-related diseases, making TRPA1 a...
4.
Iori S, Lahtela-Kakkonen M, DOnofrio C, Maietti F, Mucignat G, Bardhi A, et al.
Arch Toxicol
. 2024 Jun;
98(9):3097-3108.
PMID: 38834875
Aflatoxin B1 (AFB1) is a pro-carcinogenic compound bioactivated in the liver by cytochromes P450 (CYPs). In mammals, CYP1A and CYP3A are responsible for AFB1 metabolism, with the formation of the...
5.
Patsi H, Kilpelainen T, Jumppanen M, Uhari-Vaananen J, Wielendaele P, De Lorenzo F, et al.
J Med Chem
. 2024 Mar;
67(7):5421-5436.
PMID: 38546708
A series of novel 5-aminothiazole-based ligands for prolyl oligopeptidase (PREP) comprise selective, potent modulators of the protein-protein interaction (PPI)-mediated functions of PREP, although they are only weak inhibitors of the...
6.
Djokovic N, Rahnasto-Rilla M, Lougiakis N, Lahtela-Kakkonen M, Nikolic K
Pharmaceuticals (Basel)
. 2023 Jan;
16(1).
PMID: 36678624
A growing body of preclinical evidence recognized selective sirtuin 2 (SIRT2) inhibitors as novel therapeutics for treatment of age-related diseases. However, none of the SIRT2 inhibitors have reached clinical trials...
7.
Herrala M, Huovinen M, Jarvela E, Hellman J, Tolonen P, Lahtela-Kakkonen M, et al.
Sci Total Environ
. 2023 Jan;
867:161512.
PMID: 36626990
Plastic is a widely utilized material and polyethylene is one of the most used plastic types. Microplastics are plastic particles (size <5 mm) which are primarily a micro-size range or...
8.
Djokovic N, Ruzic D, Rahnasto-Rilla M, Srdic-Rajic T, Lahtela-Kakkonen M, Nikolic K
J Chem Inf Model
. 2022 Apr;
62(10):2571-2585.
PMID: 35467856
Considerations of binding pocket dynamics are one of the crucial aspects of the rational design of binders. Identification of alternative conformational states or cryptic subpockets could lead to the discovery...
9.
Jarvenpaa J, Perkkio M, Laitinen R, Lahtela-Kakkonen M
Sci Rep
. 2022 Feb;
12(1):2234.
PMID: 35140293
The prevalence of microplastic pollution in nature and foodstuffs is fairly well identified. However, studies of micro- or nanoplastics' cell membrane permeation and health effects in humans are lacking. Our...
10.
Jarvenpaa J, Rahnasto-Rilla M, Lahtela-Kakkonen M, Kublbeck J
Biomed Pharmacother
. 2022 Jan;
147:112652.
PMID: 35065514
Alterations in epigenetic marking, due to changes in expression or activity of epigenetic regulators, may affect cancer development and progression and thus, targeting epigenetic regulators provides potential avenues for cancer...